Malaria Diagnosis and Treatment

Clinical Presentation

• Malaria presents with fever and flu-like symptoms, including chills, headache, myalgia, and malaise, often occurring in cycles, and requires prompt treatment with appropriate antimalarial medications based on Plasmodium species and regional resistance patterns 1
• Patients with malaria may experience a range of symptoms, including nausea and vomiting, diarrhea, depressed consciousness or coma, seizures, respiratory distress, hypotension, severe anemia, hemoglobinuria, oliguria or anuria, jaundice, hemorrhagic complications, and hypoglycemia 2
• Metabolic acidosis is a potential complication of malaria 3

Diagnosis

• All febrile travelers returning from malaria-endemic areas should be evaluated for malaria, with three negative thick blood films, taken 12 hours apart, generally excluding malaria 3
• Malaria diagnosis can be performed through microscopic examination of Giemsa-stained thick and thin blood films, which is the gold standard, allowing for parasite detection, species identification, quantification of parasitemia, and differentiation between sexual and asexual forms, as recommended by the World Health Organization 4, 5
• Rapid diagnostic tests (RDTs) have a sensitivity of 67.9-100% and specificity of 93.1-100% for P. falciparum, and 66-91% sensitivity and 98-100% specificity for P. vivax 4, 5
• Nucleic Acid Amplification Tests (NAATs) are 10-100 times more sensitive than microscopy or RDTs, and can be used for diagnosis, with the following sensitivity and specificity:

4, 5

Treatment

• The World Health Organization and the Centers for Disease Control and Prevention recommend first-line treatment with intravenous artesunate, dosed at 2.4mg/kg IV at 0, 12, and 24 hours, then daily, until parasitemia <1% and patient can take oral medication, followed by completion of treatment with a full course of oral artemisinin-based combination therapy (ACT) 4, 2
• Alternative treatment options include intravenous quinine dihydrochloride, and oral medications such as chloroquine, mefloquine, and atovaquone-proguanil, with specific dosing regimens and recommendations for use in chloroquine-sensitive and resistant areas 1, 2
• Dihydroartemisinin-piperaquine (DHAePPQ) is the preferred Artemisinin-based Combination Therapy (ACT) due to its longer half-life, as stated in the Clinical Microbiology and Infection guidelines 4
• Primaquine or tafenoquine should be used for radical cure (liver hypnozoites), with G6PD testing required before administration, and primaquine should be given at 15 mg (base) daily for 14 days, or tafenoquine as a single 300 mg dose, but are contraindicated during pregnancy 4, 2
• For patients with severe G6PD deficiency, the Centers for Disease Control and Prevention recommends that primaquine should not be administered for more than 5 days due to risk of life-threatening hemolysis 2
• For patients with intermediate G6PD deficiency (>30% < 70%) and non-Mediterranean variant (A-), weekly primaquine (0.75 mg base/kg, maximum 45 mg) for 8 weeks with close monitoring for hemolysis is recommended, according to the Clinical Microbiology and Infection guidelines 4

Prevention

• Chemoprophylaxis should be started 1-2 days before entering an endemic area, continued daily during stay, and for 7 days after return, with options including chloroquine, mefloquine, and atovaquone-proguanil 1
• Travelers to endemic areas should take preventive measures, such as using insecticide-treated bed nets, wearing protective clothing, and applying insect repellents, as recommended by the Centers for Disease Control and Prevention 2, 4
• Vector control measures, such as indoor residual spraying and reduction of breeding sites, should be implemented to prevent the spread of malaria, and increasing artemisinin resistance in Greater Mekong sub-region and parts of Africa requires vigilant monitoring 2, 4

Monitoring and Treatment Failure

• The Centers for Disease Control and Prevention recommends monitoring parasitemia every 24 hours until negative for uncomplicated malaria, and every 12 hours until <1%, then every 24 hours until negative for severe malaria, with treatment failure considered if symptoms persist after 48-72 hours of chloroquine treatment, and alternative treatments such as AL, alternative ACTs, or quinine plus doxycycline/clindamycin considered for AL failure 2